Growing International Presence Atomo Diagnostics is actively expanding regionally, with recent office openings in New Zealand and ongoing efforts to enter international markets, creating opportunities to introduce new diagnostic products to additional healthcare providers and government agencies.

Expanding Product Portfolio The launch of the Swab Platform and development of innovative rapid tests such as active syphilis detection and COVID-19 tests position Atomo to capture market share in various infectious disease diagnostics, appealing to healthcare organizations seeking versatile testing solutions.

Government and Partner Funding Recent grants and government-funded orders demonstrate strong public sector support, indicating potential for sales growth through partnerships with health authorities, research institutions, and non-profit organizations involved in disease surveillance and testing.

Strategic Industry Collaborations Partnerships with reputable entities like Viatris and Burnet Institute highlight opportunities for co-developed products and joint ventures, which can help open access to new markets and customer segments, especially in infectious disease testing.

Niche Market Focus Specialization in rapid tests for infectious diseases such as HIV and syphilis makes Atomo an attractive supplier for healthcare providers, clinics, and government health programs aiming to scale up widespread, quick diagnostic testing.